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Abstract
Background: Case management has been suggested as an innovative strategy that facilitates the improvement of a 
patient's quality of life, reduction of hospital length of stay, optimization of self-care and improvement of satisfaction of 
patients and professionals involved. However, there is little evidence about the effectiveness of the patient advocacy 
case management model in clinical practice.
Therefore, the objective of our study was to examine the effects of the Dutch patient advocacy case management
model for severely disabled Multiple Sclerosis (MS) patients and their caregivers compared to usual care.
Methods/design: In this randomized controlled trial the effectiveness of casemanagement on quality of life of 
patients and their caregivers, quality of care, service use and economic aspects were evaluated. The primary outcomes 
of this study were quality of life of MS-patients and caregiver burden of caregivers.
Furthermore, we examined quality of life of caregivers, quality of care, service use and costs.
Discussion: This is a unique trial in which we examined the effectiveness of case management from a broad 
perspective. We meticulously prepared this study and applied important features and created important conditions for 
both intervention and research protocol to increase the likelihood of finding evidence for the effectiveness of patient 
advocacy case management. Concerning the intervention we anticipated to five important conditions: 1) the contrast 
between the case management intervention compared to the usual care seems to be large enough to detect 
intervention effects; 2) we included patients with complex care situations and/or were at risk for critical situations; 3) 
the case managers were familiar with disease specific health-problems and a broad spectrum of solutions; 4) case 
managers were competent and authorized to perform a medical neurological examination and worked closely with 
neurologists specialized in MS; and 5) the case managers had a regional network of professionals and health care 
organisations at their disposal, and were accepted as a coordinator of care. We also put a lot of effort on the selection of 
eligible patients, randomization and statistical methods, but also on power analysis, selection of reliable, validated and 
sensitive outcome measures, and (statistical) control of confounders.
Trial registration: Dutch Trial Register http://www.trialregister.nl. Trial ID: NTR762.
Background
Case management
Case management has been suggested as an innovative
strategy that facilitates the improvement of a patients'
quality of life, the reduction of hospital length of stay, the
optimization of self-care and improvement in the satis-
faction of the patient and the professionals involved.[1,2]
In general, case management focuses on high-risk and
high-cost populations that represent the largest part of
the expenses for health care in developed countries.[3,4]
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In case management, an individual or a small team is
responsible for navigating the patient through a complex
process in the most efficient, effective and acceptable
way.[5] Based on suggestions of the underlying dynamics,
Long [6,7] categorized the many variants of case manage-
ment into two types: the "interrogative case management
model" and the "patient advocacy" model:
▪ The predominant focus of the interrogative case man-
agement model is on the appropriateness of services dur-
ing the initial clinical decision-making process. The costs
of care in particular are recognized as representing a
legitimate argument in this process. This model, also
referred to as the "medical case management model" [8]
and the "gate-keeper model" [9] employs a physician gate-
keeper with expectations of cost containment by arrang-
ing substitution of services.
▪ The predominant focus of the patient advocacy case
management model is on a more comprehensive coordi-
nation of services across the continuum of care, viewed
from the patient perspective.[10] The case manager
assesses the changing needs of the clients, eliminates
fragmented care, and arranges for services to be pro-
vided.[7] In this model, also referred to as the socioeco-
nomic model, the treatment regimen is determined not
only by the medical needs, but also by a combination of
financial, psychological and social circumstances of the
patient.
The case management approach in the patient advo-
cacy model seems especially relevant for the growing
number of chronically ill and elderly people with complex
health problems, and is in line with the contemporary
general emphasis on patient-centered health care and the
delivery of effective health care for these patients.[11]
The Dutch case management model for the chronically ill
In the Netherlands we developed a case management
model for people with a chronic disease in a multidisci-
plinary and integrated care setting.[12] This model was
developed using literature review, four focus group meet-
ings (n = 6), and a Delphi method (n = 65) with two writ-
ten rounds and a consensus meeting. The participants of
the Delphi panel were patients and caregivers (27%),
medical and non-medical professionals (51%) and health
administrators (23%).
The final model consists of five basic assumptions and
21 characteristics and was evaluated by 92% (n = 58) of
the Delphi panel as (very) desirable for the chronically ill.
The characteristics of the Dutch case management model
for the chronically ill are similar to the characteristics of
the patient advocacy model. Most important characteris-
tics of the Dutch model are: (i) the patient-centred vision,
(ii) the focus on somatic as well as the psychosocial and
environmental problems, and (iii) the independency of
the case manager from organizational and professional
structures. In fact the patient - case manager relation can
be seen as an employer - employee relationship in which
the case manager acts under agreement of the patient.
Effectiveness of case management
There are several reasons to perform studies to evaluate
the efficacy of the patient advocacy model. The first is
that financial constraints require that we select effective
interventions that at the least maintain quality of care. A
second reason is the growing number of chronically ill
and elderly people with complex health problems. These
groups in particular seem to benefit from the patient
advocacy model in which the case manager assesses the
changing needs of the clients, eliminates fragmented
care, and arranges for services to be provided[7].
Although it is expected that less costly appropriate sub-
stitute services are likely to be used whenever possible[7],
it is important to know which effects the patient advo-
cacy model has on service use and health care costs.
There is little evidence about the effectiveness of
patient advocacy case management model in clinical
practice. However, Oeseburg et al[13] showed in a sys-
tematic review of randomized controlled trials (RCTs)
that the patient advocacy case management model did
not increase service use and costs. Moreover, there were
indications that patient advocacy case management for
chronically ill or elderly people may lead to a decrease in
service use and health care costs. Another conclusion was
that little attention was paid to other potential benefits of
patient advocacy case management such as physical
health or quality of life aspects. These potential limita-
tions tend to result in a narrowed view of the effective-
ness of patient advocacy case management.
Multiple Sclerosis (MS)
In this study we examine the effects of patient advocacy
case management among severely disabled MS patients.
MS is an inflammatory autoimmune disease of the cen-
tral nervous system and is potentially the most common
cause of neurological disability in young adults.[14] After
diagnosis the prognosis of the disease is difficult to esti-
mate and is dependent on its course. In fact, on the indi-
vidual level, MS is an unpredictable chronic disease with
a severe impact on functioning and quality of life. MS-
patients can benefit from the patient advocacy model
when the disabilities and care complexity increase. Con-
sequence of the increasing care dependency is a growing
burden and strain for the caregivers, the persons directly
involved in the care for the MS-patients. When care-
dependency increases the decision between living at
home and living in a nursing home is often based on the
caregiver burden and strength.Wynia et al. BMC Health Services Research 2010, 10:142
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Objective
The objective of our study was to examine the effects of
the Dutch patient advocacy case management model for
people with a chronic disease compared to usual care on
(i) quality of life of patients and their caregivers, (ii) qual-
ity of care, (iii) service use and economic aspects.
Expected outcomes of patient advocacy case manage-
ment compared to the usual care were: (i) improved qual-
ity of life for both, patients and caregivers (primary
outcome patients), (ii) improved quality of care, (iii) less
caregiver burden or strain (primary outcome caregivers),
and (iv) equal or less service use and costs.
This paper will provide a detailed description of the
study design and research protocol.
Methods/design
Study design and setting
The study was a randomized controlled trial performed
among severely disabled MS-patients known to the
Groningen MS center, and their caregivers. Study partici-
pants received either case management according to the
Dutch patient advocacy case management model or the
usual care during the intervention period of 15 months
between September 2006 and January 2008.
Randomisation procedure
Eligible patients (and their caregivers) were randomly
allocated - with a computerized programme - to either
the intervention group or the control group using a ran-
domized block design.[15] This approach allowed us to
control our findings for characteristics of the partici-
pants. Blocking variables in our study were severity of
limitations in walking (yes/no wheelchair dependency),
having a partner or caregiver (yes/no), educational level
(low/middle/high level), having children living at home
(yes/no), and performing paid work (yes/no).
Ethical approval
The study has been approved by the University Medical
Center Groningen medical ethical committee (Reference
M06.040514).
Study population MS-patients
The study was performed among MS-patients known to
the Groningen MS center, which is part of the University
hospital. Patients lived in a wide surrounding area around
the hospital with a maximum distance of about 100 kilo-
metres. As it is known that case management is most
effective in high-risk populations, eligible patients should
be characterized by complex care situations and/or be at
risk for exacerbations of critical situations. We therefore
included:
▪ MS-patients with increasing limitations in walking
ability who were at risk for becoming completely depen-
dent of a wheelchair and help from others. This phase is
especially complex because of the (potential) changes in
psychosocial circumstances and necessary environmental
changes. Furthermore, this phase is critical for partner-
ships because of the changing roles between the partners
and the growing caregiver burden.
▪ MS-patients that were completely wheelchair depen-
dent but not essentially restricted to bed much of day.
This phase is especially complex because of the growing
risk of physical complications and care dependency. This
phase is also critical for the caregiver because of increas-
ing caregiver burden. In summary, admission to a nursing
home is a threatening solution for all health-related and
caregiver problems.
To define our sample of severely disabled MS-patients
we used the neurological classification system, the
Expanded Disability Status Scale (EDSS). The EDSS is a
c o m m o n l y  u s e d  d i s a b i l i t y  m e a s u r e  f o r  M S [ 1 6 ]  w i t h  a
twenty-points scoring scale starting at 0 (no disability)
and increasing at half point increments to a maximum
score of 10 (death due to MS).
Eligible patients with increasing limitations in walking
were defined as patients with an EDSS score ranging from
4.5 to 7.0 (= able to walk without rest some 300 meters or
less without assistance or with canes or other assist
devices). Patients essentially restricted to wheelchair but
not essentially restricted to bed much of day were defined
with an EDSS score ranging from 7.0 to 8.5). Further-
more, patients should be of adult age, live independently
in the community and not in a nursing home or other
institution for long term referral. Patients should not par-
ticipate in another intervention study (Table 1).
In total 227 eligible patients with the diagnosis MS and
a  s uita ble  EDSS  sc or e  w e r e  se lect ed fr o m  our  hos pita l
registration system and invited by mail to participate in
Table 1: Eligibility criteria for the Dutch patient advocacy 
case management study.
Inclusion criteria
- Adult people older than 18 years
- Diagnosed with MS
- EDSS score with a range of 4.5 to 8.5
- Living at home
- Treated by neurologists of the Groningen MS centre, which is 
part of the University hospital
Exclusion criteria
- No clear diagnose for MS
- EDSS score below 4.5 or above 8
- Living in a nursing home or other institution for long term 
referral
- Participation in another MS related study
- Living at a larger distance from the hospital than 100 kilometersWynia et al. BMC Health Services Research 2010, 10:142
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the study according to the Informed Consent procedure
in our study protocol. Patients were informed about the
intervention, the intervention period, the fact that there
was an equal chance to get allocated to the case manage-
ment group or to the usual care group, and the efforts
asked by the researchers to fill out a number of question-
naires at the start and at the end of the intervention
period of 15 months.
Finally, 102 MS-patients (45%) responded to our invita-
tion to participate in our study. There were no differences
between respondents and non-respondents concerning
age (T-test p-value .332) and gender (Mann-Whitney Test
p-value .374). Respondents answered the questions nec-
essary to check the inclusion criteria and for the random-
ized block procedure. From these questions - and from
telephone calls by the researcher - it became clear that
three patients were living in a nursing home or had no
walking disabilities. In total, 99 patients (44% response)
agreed to participate in the study and signed the
Informed Consent paper including the consent for the
case manager to perform the usual neurological evalua-
t i o n  u n d e r  s u p e rv i s i o n  o f  t h e  n e u r o l o g i s t ,  t o  r e a d  t h e
medical dossier, and to contact the general practitioner
when necessary. The computerized randomization pro-
gramme assigned 51 patients to the case management
group, while 48 patients were included in the usual care
group (Figure 1).
Study population Caregivers
Caregivers of participating MS patients were invited to
participate in the study according to the Informed Con-
sent procedure in our study protocol. Caregivers were
informed about the intervention, the intervention period
and the special attention of the case manager for the care-
giver burden, the fact that there was an equal change to
get allocated to the case management group or to the
usual care group, and the efforts asked by the researchers
to fill out a number of questionnaires at the start and at
the end of the intervention period. In total, 77 caregivers
agreed to participate in the study and signed the
Informed Consent paper: Thirty-nine caregivers were
included - with the MS-patients they were related to - in
the case management group and 38 caregivers were
included in the usual care group (Figure 1).
Case managers
Case management was performed by two experienced
professionals in care-coordination for people with MS.
One case manager was a nurse practitioner of the MS
center of our university hospital while the other case
manager was a nurse specialist in chronic neurological
diseases especially in MS of a large home healthcare
organisation. Both case managers were familiar with dis-
ease specific health-problems and a broad spectrum of
solutions for these problems. Furthermore, both case
managers were competent and authorized to perform a
medical neurological examination and worked closely
with the neurologists specialized in MS.
Both case managers had a regional network of profes-
sionals and health care organisations at their disposal.
Because of their years of experience in the regional MS-
care in the community and hospital the acceptance of the
case manager as the coordinator for care delivery was
accepted. The case managers were not limited to organi-
zational boundaries in allocating services. Patients' pref-
erences were leading in the selection of the most
appropriate service.
Intervention: Dutch Patient Advocacy Case management
Elements of the Dutch Patient Advocacy Case manage-
ment model with regular home visits were:
▪ Use of valid and reliable self-report assessment tools:
The Multiple Sclerosis Impact Profile (MSIP) [17,18] for
the disease specific health-status of the patients, and the
Caregiver Strain Index (CSI) [19] to assess the caregiver
burden. In the paragraph about outcome measures these
assessment tools are described.
▪ Regular assessments (each five months, three times
during the study) during a visit at the patients' home:
Patients prepared themselves by filling-out the MSIP.
Caregivers prepared themselves by filling-out questions
concerning caregiver burden. Casemanagers prepared
Figure 1 Flowchart Dutch patient advocacy case management 
intervention among severely disabled MS-patients. Summary of 
the progress through the phases of the study until the allocation of the 
participants to each treatment arm.
Eligible patients 
n=227 
Response 
Patients n=102 
Caregivers n=77 
Non-response 
Patients n=125 
Included 
Patients n=99 
Caregivers n=77 
Excluded 
Patients n=3 
-  In nursing home 
- EDSS ≤ 4
Case management Group 
Patients n=51 
Caregivers n=39 
Control Group 
Patients n=48 
Caregivers n=38 
Follow up 
15 months 
Follow up 
15 months 
Analyses  Analyses Wynia et al. BMC Health Services Research 2010, 10:142
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themselves by reading the filled-out questionnaires. Dur-
ing the assessment the filled-out questionnaires were
guidelines for the discussion for the patient, caregiver and
case manager.
▪ Medical examination and treatment: During each visit
the case managers also performed a medical examination
as a part of the total assessment. Concerning neurological
medical aspects, like changes in medical treatment, the
case managers were supervised by the neurologists of the
MS centre structurally (during weekly meetings) and inci-
dentally (when necessary). For regular medical treatment
the case managers contacted the patients' general practi-
tioner.
▪ Care plan: using the outcomes of the assessments, pri-
orities set by the patient and caregiver and advise for pos-
sible solutions given by the case manager, a
multidisciplinary and patient-centred care plan was com-
posed. Health problems, preferred solution directions,
actions to be undertaken and agreements about who is
doing what and when were registered in the care plan.
▪ Navigation and monitoring: after the care plan was
established and put into action, there were regular con-
tacts between the case manager and the patient and care-
giver about the progress in the realization of the plan and
the effects on patient and caregiver. These contacts were
mostly telephone contacts and sometimes additional
home visits.
▪ Evaluation: during each follow-up home visit the care
plan was evaluated and results were described.
Usual Care: regular consultations in the hospital
Patients and caregivers in the control group received the
usual care during regular consultations with their neurol-
ogist in the Groningen MS center. Normally, patients vis-
ited their neurologist about two times a year. This
frequency may decrease or increase depending of the
patients' personal preference and actual health-status.
The time planned for a standard consultation was 20
minutes. Consultations focused on the neurological
health problems of the patient. For non-neurological
issues patients were referred to their general practitioner
or other health professionals. For non-medical issues
patients were referred to a nurse specialist.
Procedure of data collection
After inclusion in the study and assignment to either the
intervention or the control group, patients were informed
by mail about their inclusion and allocation. Patients
included in the control group were advised to make an
appointment with their neurologist as they were used to
do. Patients included in the experimental group were ran-
domly assigned to one of the two case managers.
Data were collected with self-report outcome measures
on quality of life (patients and caregivers), quality of care
(patients) and caregiver burden (caregivers) at two
moments during the study: i) at baseline, after inclusion
in the study and randomization to one of the research
groups, ii) 15 months after the baseline assessment a few
weeks after finishing the intervention. See also Table 2.
During the intervention data were collected continu-
ously about: i) health problems, interventions and out-
comes from the care plans (case management group) and
the medical records (control group), and ii) about service
use and costs from a structured costs booklet for the
p a t i e n t s  i n  b o t h  r e s e a r c h  g r o u p s  a n d  s t r u c t u r e d  c a s e
management records. See also Table 2.
Outcome measures
General Quality of Life (primary outcome patients)
The World Health Organization Quality of Life, abbrevi-
ated version (WHOQOL-BREF)[20] is a generic quality
of life measure with a broad scope, including environ-
mental aspects. It consists of 26 items in four constructs:
'physical health and autonomy', 'psychological health',
'social relationships' and 'environment', and two separate
questions: 'overall quality of life' and 'overall satisfaction
with health'. For each scale, item scores were coded,
summed and transferred to a scale of 0 (worst health) to
20 (best health). In our former study among MS-patients
the WHOQOL-BREF showed satisfactory levels of inter-
nal consistency with Cronbach's alpha = .63/.81[17].
Participation and autonomy
The Impact on Participation and Autonomy Question-
naire (IPAQ) [21,22] is a domain specific quality of life
measure covering participation aspects. The IPAQ con-
sists of twenty-five items focusing on person-perceived
participation and autonomy. The instrument assesses two
aspects of participation: perceived participation and the
perceived problem. In this study the perceived participa-
tion aspect was used. The sub-domains are autonomy
indoors, family role, autonomy outdoors and social rela-
tions. Item scores are graded on a five-point rating scale
with discrete responses, ranging from 1 (very good) to 5
(very poor). Scores are summed for each domain. In a for-
mer study among MS-patients the IPAQ showed satisfac-
tory levels of internal consistency with Cronbach's alpha
= .86/.94.[17]
Depression
The Beck Depression Inventory-II (BDI-II) measures the
severity of self-reported depression in adolescents and
adults.[23,24] The BDI-II consists of 21 items reflecting
the diagnostic criteria for major depressive disorders that
are described in the American Psychiatric Associations
Diagnostic and Statistical Manual of Mental Disorders,
4th  Edition (DSM-IV).[25] Respondents are asked to
describe themselves for the "past two weeks, including
today" by selecting a response option for each item. Item
scores are graded on a 4-point scale ranging from 0 (noWynia et al. BMC Health Services Research 2010, 10:142
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negative feelings) to 3 (severe negative feelings). Scores
are summed and total scores can range from 0 to 64. Sug-
gested cut-off values are the following: 0-10 = no depres-
sion; 11-17 = mild depression; 18-23 = moderate
depression; 24-39 = severe depression.
MS-specific health-status
The Multiple Sclerosis Impact Profile (MSIP)[17] is a self-
report measure for people with MS to assess disability
and disability perception and is based on the Interna-
tional Classification of Functioning, Disability and Health
(ICF). The MSIP consists of two related parts: 1) the
MSIP-Disability (MSIP-D) part, reporting the prevalence
and severity of MS-related disabilities and 2) the MSIP-
Disability Perception (MSIP-DP) part, reflecting the per-
ception of reported disabilities. A disability perception
item is directly linked to each disability item. The MSIP
consists of 36 items for each part, divided into three func-
tioning scales: 'Muscle and movement functions', 'Excre-
tion and reproductive functions' and 'Mental functions';
two activities scales: 'Basic movement activities' and
'Activities of Daily Living'; one participation scale: 'Partic-
ipation in Life situations'; and one environmental factors
scale: 'Environmental factors'; and four additional impair-
ment items for Fatigue, Pain, Seeing functions and
Speech functions. Scoring options for the MSIP-disability
part range from 0 (no disability) to 3 or 4 (complete dis-
ability). Summed scores for the disability domains indi-
cate the extent of disability. A lower disability score
means less serious disability. Scoring options for the
MSIP-disability perception part range from 0 (no, never)
to 3 (yes, always). Summed scores for the disability per-
ception domains indicate the extent to which patients
perceive the reported disabilities as problematic. A lower
disability perception score means that a reported disabil-
ity is perceived as less problematic.
The internal consistency tests of MSIP scales showed
good levels of internal consistency with Cronbach's
Alpha's = .80/.90 for most scales, and satisfying and weak
Cronbach's Alpha's for the mental functioning scales (.62/
.65) and the 'Environmental' scales (.49/.50).[17,18]
Overall Quality of Care
The 'Client Satisfaction Questionnaire (CSQ-8)'[26] con-
sists of eight items belonging to one domain: satisfaction
with the received care. Items can be scored on a scale
ranging from 1 (very negative) to 4 (very positive). The
total score therefore can range from 8 (most dissatisfied)
to 32 (most satisfied). The Dutch version of the CSQ-8
showed similar high internal consistency (Cronbach's
Alpha = 0.91) as the original English version (Cronbach's
Alpha = 0.93).[27]
Care plans and medical letter
Two researchers independently analyzed each care plan
(case management group) and medical letter (control
group) for the reported health problems of the patients,
caregiver burden, applied interventions, and patient and
caregiver outcomes. Differences between the researchers
were resolved through discussion or with reference to a
third researcher when necessary.
Table 2: Measures
Variable Measure Applied to T0 T1 Cont
Demographics Usual questions Patient and Caregiver X
Medical history Usual questions Patient X
Quality of Life WHOQOL-BREF Patient and Caregiver X X
MSIP Patient X X
IPAQ
BDI-II
Patient and Caregiver X X
BDI-II Patient and Caregiver X X
Quality of Care CSQ Patient and Caregiver X X
Care plan/Medical letter - X
EQ-5D Patient and Caregiver X X
Caregiver burden General Inventory Caregiver X -
CSI Caregiver X X
Costs Care plan/Medical letter - X
Costs booklet Patient X
T0 = at baseline after before randomization. T1 = 15 months after finishing the intervention. Cont. = continuous. WHOQOL-BREF = World 
Health Organization Quality of Life, abbreviated version; MSIP = Multiple Sclerosis Impact Profile; IPAQ = Impact on Participation and 
Autonomy Questionnaire; BDI-II = Beck Depression Inventory-II; CSQ = Consumer Satisfaction Questionnaire; EQ-5D = Health related Quality 
of Life Index; CSI = Caregiver Strain IndexWynia et al. BMC Health Services Research 2010, 10:142
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Findings were recorded and categorized in SPSS.
▪ Disease related health problems were categorized into
the MSIP-categories;
▪ Caregiver burden problems were summarized as care-
giver problems;
▪ Interventions were clustered into categories of 'giving
information', 'consultation of medical and non medical
specialists or organizations', 'refers medical and non
medical specialists or organizations', 'acquiring assist
devices or home adjustments', 'arranging supplementary
care ad home' or 'arranging (short) stay or day treatment'
▪ Outcomes were recorded in terms of 'improved',
'worsened' or 'no change'
Opinion about case management
To examine the patients and caregivers opinion about the
case management process and outcomes we developed
thirty statements about case management. These state-
ments were based on the assumptions and characteristics
defined in the Delphi study in which we developed the
Dutch casemanagement model [12]. Patients were asked
to give their opinion about their personal experience
(what case management did bring them), and the case
management processes (e.g. the home visits, the care
plans, the casemanagers actions). We linked four
response options to each statement: I fully disagree, I dis-
agree, I agree, I fully agree.
Caregiver context and tasks
To gain insight into the caregivers tasks and time spent,
relevant contextual factors (age, gender, relation to MS-
patient, health status), personal experiences with care-
giver tasks (e.g. (not) heavy, (not) problematic) we devel-
oped an inventory. Relevant items for this inventory were
selected from existing questionnaires applied in other
studies about caregiver tasks and caregiver burden.
Caregiver Burden (primary outcome caregivers)
The Caregiver Strain Index (CSI)[28] measures caregiver
burden related to care provision. The CSI can be used as a
tool to identify caregivers with potential care giving bur-
den and strain. The CSI consists of 13 items with at least
one item for each of the following major domains:
Employment, Financial, Physical, Social, and Time. Posi-
tive responses to seven or more items on the index indi-
cate a greater level of strain. Positive responses on four to
six items of the index indicates an increased burden,
while positive responses on seven to nine items indicates
a risk for overburdening or strain, and a positive response
on ten to twelve index items indicates a clear overload or
strain.
Economic evaluation
For economic evaluation from the societal perspective
data on service use and indirect costs were collected from
several sources:
▪ Pa tients in both research groups filled out a struc -
tured costs booklet each three months.
▪ Casemanagers recorded travelling costs and time
spent on each patient, while for comparison with the
costs for usual care the standard costs for a consultation
with a neurologist were used.
▪ We analyzed care plans (case management group) and
the medical records (control group) for data on service
use.
▪ Patients and caregivers filled out the EQ-5D for calcu-
lating the costs of an additional day of life. The EQ-5D is a
health-related quality of life measure consisting of i) five
dimensions (mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression) each of which can take one
of three responses reflecting three levels of severity (no
problems/some or moderate problems/extreme prob-
lems) within a particular EQ-5D dimension, and ii) a
standard vertical 20 cm visual analogue scale (similar to a
thermometer) for recording an individual's rating for
their current health-related quality of life.
Sample size calculations
We used samples of MS-patients as well as samples of
caregivers and expected that about 60% of the caregivers
would give their informed consent to participate in the
study. Sample size calculations were targeted on a clini-
cally relevant change in quality of life for the smallest
group, the caregivers. A clinically relevant change in the
primary outcome measure of quality of life (WHOQOL-
BREF) of 1.5 points on a scale ranging from 0 (worst qual-
ity of life) to 20 (best quality of life) and standard devia-
tion of 2.0 can be found with a power of 0.815 in
comparing two groups of 30 subjects is applied. The clin-
ically relevant change of 1.5 points and standard devia-
tion of 2.0 were found in a former study among 530 MS
patients [17,29] Consequently the sample size for the MS-
patients should consist of 50 subjects for each research
group. Power analysis for this sample size showed a
power of 0.960.
Potential confounders and effect modifiers
To prevent confounding in the control group during the
consultations in the hospital were not performed by the
casemanagers involved in the project during the inter-
vention period. For special non-medical interventions
casemanagers could be consulted by the neurologist,
while contacts of the casemanagers with patients from
the control group were limited to that specific interven-
tion they were asked for by the neurologist.
Statistical analysis
Primary analysis will focus on comparison of samples and
differences between the intervention group and control
group after intervention concerning the primary outcomeWynia et al. BMC Health Services Research 2010, 10:142
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measures: quality of life for the MS-patients and care-
giver burden for the caregivers. Secondary analysis will
focus on: 1) the comparison between research groups for
the secondary variables concerning quality of life, quality
of care, service use and costs, and 2) the explanation on
the outcomes on the primary outcome variables. Finally,
analysis will focus on the patient-caregiver couples: e.g.
the impact of the patients' disability and disability percep-
tion (MSIP scales) on the caregiver strain en caregiver
quality of life.
For comparison of samples and estimation of differ-
ences in outcomes between the case management and
usual care groups before and after the intervention period
we used t-tests for continuous variables, Chi-square tests
and Fisher exact tests when appropriate, and differences
of proportions tests[30] for comparisons with categorical
variables. For multiple group comparisons we will use
one-way ANOVA analysis to determine statistically sig-
nificant differences between subgroups. Effect sizes will
be calculated only for statistically significant group differ-
ences (p < 0.05) with post hoc tests (with Bonferroni cor-
rection for capitalization on chance in multiple testing).
According to Cohen's thresholds [31] an ES of < 0.20 indi-
cates a trivial effect, an ES of ≥ 0.20 to < 0.50 a small
effect, an ES of ≥ 0.50 to < 0.80 a moderate effect and an
ES ≥ 0.80 a large effect. An ES ≥ 0.20 reflects a clinical rel-
evant difference between groups.[32]
The impact of case management on quality of life
(patients and caregivers) and on caregiver burden (care-
givers) will be assessed using hierarchical regression anal-
ysis with each of the Quality of Life scale variables,
participation scale variables and depression variable
(patients and caregivers) and Caregiver Strain Index out-
come variable (caregiver) as dependent variables. Rele-
vant other patient, disease related and caregiver variables
with a statistically significant correlation with the depen-
dent variables will be include in the analysis as covariates.
The primary economic evaluation will be a cost-effec-
tiveness analysis from the societal perspective. In a sec-
ondary cost-utility analysis, quality adjusted life years
(QUALYs) will be calculated based on EQ-5D values.
Discussion
In this paper we have reported on the background and
the study protocol of a unique randomized controlled
trial to examine the effects of the Dutch patient advocacy
case management model. We meticulously prepared this
study and applied important features and created impor-
tant conditions for both intervention and research proto-
col to increase the likelihood of finding evidence for the
effectiveness of patient advocacy case management.
Concerning the intervention we anticipated to four
important conditions: Firstly, the contrast between the
case management intervention - in combination with
home-visits - compared to the usual care seems to be
large enough to detect intervention effects. Secondly, as it
is known that case management is most effective in high-
risk populations, we decided that eligible patients should
be characterized by complex care situations and/or
should be at risk for exacerbations or critical situations.
Thirdly, the case managers in this study were familiar
with disease specific health-problems and a broad spec-
trum of solutions for these problems. Furthermore, both
case managers were competent and authorized to per-
form a medical neurological examination and worked
closely with the neurologists specialized in MS. Finally,
the case managers had a regional network of profession-
als and health care organisations at their disposal, and
were accepted in the community and in the hospital as a
coordinator of care.
Apart from the intervention, the study design is of
essential importance for finding evidence for the effec-
tiveness of case management. We therefore developed a
powerful design: We put a lot of effort on the selection of
eligible patients, randomization and statistical methods,
but also on power analysis, the selection of reliable, vali-
dated and sensitive outcome measures, and (statistical)
control of confounders, and finally the assessment by a
medical ethics committee.
We decided against performing a feasibility study.
Arguments were that the intervention (casemanagement)
was already tested on a small scale in days-to-day prac-
tice, and evaluated by patients, casemanagers and other
relevant health professionals. Furthermore most applied
measures, utilized in the trial, were tested in earlier MS-
related studies. In other words, we acquired sufficient
evidence for feasibility and based on these experiences we
were confident about the adequacy of our study design
and data collection plan.
A possible limitation of the study is the duration of the
intervention period. There are indications suggesting that
there is a so-called 'investment effect' concerning health
care costs for 'steady-state programmes' such as patient
advocacy case management.[33] This phenomenon was
found in a number of experimental studies[2,34-36] and
implicates that in the first year of a study, the health care
costs in the experimental group were more than those
incurred for patients in the usual care group, while in the
final years of these studies costs for the usual care group
exceeded those for the experimental group. Although
there is no evidence it seems reasonable to assume that
this investment effect for costs also is applicable for other
outcome variables like quality of life. Despite our efforts
made to organize a prolonged study, we succeeded in
organizing an intervention period with duration of 15
months.Wynia et al. BMC Health Services Research 2010, 10:142
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